Original Article

You have full text access to this OnlineOpen article

Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer

  1. Jue Wang MD1,†,*,
  2. Yong Fang Kuo PhD2,3,
  3. Jean Freeman PhD2,3,
  4. Avi B. Markowitz MD2,
  5. James S. Goodwin MD2,3

Article first published online: 26 NOV 2007

DOI: 10.1002/cncr.23181

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 382–390, 15 January 2008

Additional Information

How to Cite

Wang, J., Kuo, Y. F., Freeman, J., Markowitz, A. B. and Goodwin, J. S. (2008), Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer, 112: 382–390. doi: 10.1002/cncr.23181

Author Information

  1. 1

    Department of Internal Medicine, Section of Oncology-Hematology, University of Nebraska Medical Center, Omaha, Nebraska

  2. 2

    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

  3. 3

    Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas

  1. †

    Fax: (402) 559-6520.

*Department of Internal Medicine, Section of Oncology-Hematology, University of Nebraska Medical Center, Omaha, NE 68198-7680

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 26 NOV 2007
  3. Manuscript Accepted: 15 AUG 2007
  4. Manuscript Revised: 10 JUL 2007
  5. Manuscript Received: 15 MAY 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (245K)

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Smigal C,Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106–130.
    Direct Link:
  • 2
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533–543.
  • 3
    Spira A,Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350: 379–392.
  • 4
    Immerman SC,Vanecko RM,Fry WA,Head LR,Shields TW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg. 1981; 32: 23–27.
  • 5
    Rosell R,Felip E,Maestre J, et al. The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer. 2001; 34( suppl 3): S63–S74.
  • 6
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111: 1710–1717.
  • 7
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899–909.
  • 8
    Le Chevalier T, for the IALT Investigators. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT) cisplatin-based chemotherapy (CT) versus no CT in 1867 patients with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2003: 22. Abstract 6.
  • 9
    Arriagada R,Bergman B,Dunant A,Le Chevalier T,Pignon JP,Vansteenkiste J;International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351–360.
  • 10
    Winton TL,Livingston R,Johnson D, et al. Vinorelbine and cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352: 2589–2597.
  • 11
    Strauss GM,Herndon JE,Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 365.
  • 12
    Douillard J,Rosell R,Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts); final results after 70-month median follow-up [abstract]. Proc Am Soc Clin Oncol. 2005; 24: 619.
  • 13
    Scagliotti GV,Fossati R,Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003; 95: 1453–1461.
  • 14
    Waller D,Peake MD,Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004; 26: 173–182.
  • 15
    Tada H,Tsuchiya R,Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer. 2004; 43: 167–173.
  • 16
    Keller SM,Adak S,Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000; 343: 1217–1222.
  • 17
    Goodwin JS,Hunt WC,Humble CG,Key CR,Samet JM. Cancer treatment protocols. Who gets chosen? Arch Intern Med. 1988; 148: 2258–2260.
  • 18
    Baldwin LM,Adamache W,Klabunde CN, et al. Linking physician characteristics and Medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002; 40( 8 suppl): IV-82–IV-95.
  • 19
    Charlson ME,Pompei P,Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373–383.
  • 20
    Mackillop WJ,O'Sullivan B,Ward GK. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys. 1987; 13: 929–934.
  • 21
    Palmer MJ,O'Sullivan B,Steele R,Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol. 1990; 19: 17–28.
  • 22
    Greco FA,Hainsworth JD. Paclitaxel-based therapy in non-small-cell lung cancer: improved third generation chemotherapy. Ann Oncol. 1999; 10( suppl 5): S63–S67.
  • 23
    Greco FA,Burris HA3rd,Gray JR, et al. Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network. Cancer. 2001; 92: 2142–2147.
    Direct Link:
  • 24
    Fagerlin A,Zikmund-Fisher BJ,Ubel PA. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Making. 2005; 25: 614–619.
  • 25
    Langer CJ,Moughan J,Movsas B, et al. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer. 2005; 48: 93–102.
  • 26
    Chien CR,Lai MS. Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center. Am J Med Qual. 2006; 21: 408–414.
  • 27
    Mahmud SM,Reilly M,Comber H. Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer. 2003; 41: 57–64.
  • 28
    Logan DM,Lochrin CA,Darling G,Eady A,Newman TE,Evans WK. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group. Cancer Prev Control. 1997; 1: 366–378.
  • 29
    Choong NW,Vokes EE. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. 2005; 7( suppl 3): S98–S104.
  • 30
    Brown JS,Eraut D,Trask C,Davision AG. Age and treatment of lung cancer. Thorax. 1996; 51: 564–568.
  • 31
    de Rijke JM,Schouten LJ,ten Velde GP, et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 2004; 46: 233–245.
  • 32
    Earle CC,Venditti LN,Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000; 117: 1239–1246.
  • 33
    Goodwin JS,Hunt WC,Samet JM. Determinants of cancer therapy in elderly patients. Cancer. 1993; 72: 594–601.
    Direct Link:
  • 34
    Goodwin JS,Hunt WC,Samet JM. A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer. Arch Intern Med. 1991; 151: 366–370.
  • 35
    Goodwin JS,Hunt WC,Key CR,Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA. 1987; 258: 3125–3130.
  • 36
    Stiggelbout AM,Jansen SJ,Otten W,Baas-Thijssen MC,van Slooten H,van de Velde CJ. How important is the opinion of significant others to cancer patients' adjuvant chemotherapy decision-making? Support Care Cancer. 2007; 15: 319–325.
  • 37
    Earle CC,Neumann PJ,Gelber RD,Weinstein MC,Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002; 20: 1786–1792.
  • 38
    Luo R,Giordano SH,Freeman JL,Zhang D,Goodwin JS. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006; 11: 1025–1033.
  • 39
    Luo R,Giordano SH,Zhang DD,Freeman J,Goodwin JS. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer. 2007; 109: 975–982.
    Direct Link:
  • 40
    Gridelli C,Perrone F,Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997; 33: 2313–2314.
  • 41
    Rosell R,Gatzemeier U,Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13: 1539–1549.
  • 42
    Lokich J,Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998; 9: 13–21.
  • 43
    Schiller JH,Harrington D,Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002; 346: 92–98.
  • 44
    Simon GR,Bunn PAJr. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21: 87–104.
  • 45
    Ramalingam S,Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother. 2002; 3: 1693–1709.
  • 46
    Pepe C,Hasan B,Winton TL, et al.; National Cancer Institute of Canada, Intergroup Study JBR.10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. J Clin Oncol. 2007; 25: 1553–1561.
  • 47
    Giordano SH,Duan Z,Kuo YF,Hortobagyi GN,Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006; 24: 2750–2756.
  • 48
    Extermann M,Overcash J,Lyman GH,Parr J,Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 1582–1587.
  • 49
    Repetto L,Venturino A,Vercelli M, et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer. 1998; 82: 760–765.
    Direct Link:
View Full Article (HTML) Get PDF (245K)